165 related articles for article (PubMed ID: 23187773)
61. [Multiple myeloma: progress in management aimed at improving QoL].
Abe M
Rinsho Ketsueki; 2016; 57(10):2104-2112. PubMed ID: 27795520
[TBL] [Abstract][Full Text] [Related]
62. Antibody-based targeting of BCMA in multiple myeloma.
Morgan GJ; Williams L
Lancet Oncol; 2020 Feb; 21(2):186-187. PubMed ID: 32007191
[No Abstract] [Full Text] [Related]
63. Advances in CAR T-cell therapy for the treatment of multiple myeloma.
Shah N
Clin Adv Hematol Oncol; 2020 Jun; 18(6):316-318. PubMed ID: 32649653
[No Abstract] [Full Text] [Related]
64. Antibodies Create Killer Bonds in Myeloma.
Chesi M; Fonseca R
Cancer Cell; 2017 Mar; 31(3):305-307. PubMed ID: 28292432
[TBL] [Abstract][Full Text] [Related]
65. How I treat elderly patients with myeloma.
Mehta J; Cavo M; Singhal S
Blood; 2010 Sep; 116(13):2215-23. PubMed ID: 20644120
[TBL] [Abstract][Full Text] [Related]
66. Innate-like T cell profile in myeloma: Severe deficiency of Vγ9Vδ2 T cells in aminobisphosphonate-treated patients.
Walsh M; White G; Romeril K; Buyck H; Stephens M; Brooks C; Weinkove R
Leuk Lymphoma; 2016; 57(4):977-80. PubMed ID: 26327461
[No Abstract] [Full Text] [Related]
67. Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients.
Bera TK; Abe Y; Ise T; Oberle A; Gallardo D; Liu XF; Nagata S; Binder M; Pastan I
Leukemia; 2018 Feb; 32(2):569-572. PubMed ID: 29149102
[No Abstract] [Full Text] [Related]
68. The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.
Dosani T; Carlsten M; Maric I; Landgren O
Blood Cancer J; 2015 Apr; 5(4):e306. PubMed ID: 25885426
[TBL] [Abstract][Full Text] [Related]
69. Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies.
Kumar S
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):518-524. PubMed ID: 29222300
[TBL] [Abstract][Full Text] [Related]
70. Myeloma research on the move.
Ludwig H
Blood Cancer J; 2021 Sep; 11(9):155. PubMed ID: 34535632
[No Abstract] [Full Text] [Related]
71. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives.
Lonial S; Durie B; Palumbo A; San-Miguel J
Leukemia; 2016 Mar; 30(3):526-35. PubMed ID: 26265184
[TBL] [Abstract][Full Text] [Related]
72. Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy.
Kleber M; Udi J; Metzke B; Terpos E; Roodmann GD; Morgan G; Dispenzieri A; Einsele H; Wäsch R; Engelhardt M
Leuk Lymphoma; 2012 Jun; 53(6):1057-61. PubMed ID: 22149167
[TBL] [Abstract][Full Text] [Related]
73. Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches.
Szalat R; Munshi NC
Am Soc Clin Oncol Educ Book; 2016; 35():e442-8. PubMed ID: 27249752
[TBL] [Abstract][Full Text] [Related]
74. [I. Proteasome inhibitor for treatment of multiple myeloma].
Murakami H; Saito T; Handa H
Gan To Kagaku Ryoho; 2013 May; 40(5):583-8. PubMed ID: 23957065
[No Abstract] [Full Text] [Related]
75. Multiple myeloma.
Chavda SJ; Yong K
Br J Hosp Med (Lond); 2017 Feb; 78(2):C21-C27. PubMed ID: 28165783
[No Abstract] [Full Text] [Related]
76. Cohort analysis of FISH testing of CD138(+) cells in relapsed multiple myeloma: implications for prognosis and choice of therapy.
Smith D; Stephenson C; Percy L; Lach A; Chatters S; Kempski H; Yong K
Br J Haematol; 2015 Dec; 171(5):881-3. PubMed ID: 25899469
[No Abstract] [Full Text] [Related]
77. Treatment of plasma cell myeloma.
Bergsagel DE
Annu Rev Med; 1979; 30():431-43. PubMed ID: 162450
[No Abstract] [Full Text] [Related]
78. Current Controversies in the Management of Myeloma Bone Disease.
Silbermann R; Roodman GD
J Cell Physiol; 2016 Nov; 231(11):2374-9. PubMed ID: 26910829
[TBL] [Abstract][Full Text] [Related]
79. Multiple myeloma: genome sequencing, drug development and the future outlook.
Stewart AK; Patience J
Expert Rev Hematol; 2014 Feb; 7(1):9-11. PubMed ID: 24405278
[TBL] [Abstract][Full Text] [Related]
80. Treatment options for myeloma.
Meenaghan T; Kelly M; Dowling M
Br J Nurs; 2013 Oct 10-23; 22(18):1084, 1086. PubMed ID: 24121856
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
